In Prostate Cancer, Focus on AR Signaling Sharpens
James L. Mohler, MD
A deeper understanding of androgen receptor (AR) signaling in castration-resistant prostate cancer (CRPC) has created an opportunity to deliver more effective therapies earlier in the treatment timeline, according to James L. Mohler, MD.
In fact, Mohler believes a strategy of “androgen annihilation” may be the optimal path to curative treatment of men at risk of dying from the disease.
Mohler is associate director and senior vice president for Translational Research at Roswell Park Cancer Institute in Buffalo, New York, where he serves as chair of the Department of Urology and as a professor of Oncology. He also chairs the National Comprehensive Cancer Network’s Prostate Cancer Panel.
During a presentation and interview at the Targeted Therapies congress, Mohler indicated that expanded knowledge about the science of prostate cancer is pointing the way not only to new therapeutics, but also to a new treatment paradigm for CRPC.
In the past 18 months, the FDA has approved two new oral drugs with different mechanisms of action for interfering with androgen activity. In April 2011, the agency approved abiraterone acetate (Zytiga) in combination with prednisone to treat patients with mCRPC who have received prior docetaxel therapy. In August, enzalutamide (Xtandi) gained approval for a similar patient population. Additional agents are in development. (Table).
Table. Agents Targeting Androgen Receptor Signaling
(approved or under study)
|Given in combination with prednisone to patients with mCRPC who have received prior docetaxel||Inhibits CYP17 enzyme activity||Janssen Biotech (Johnson & Johnson)||FDA approved April 2011|
|mCRPC who have previously received docetaxel||Inhibits androgen binding to ARs, AR nuclear translocation and interaction with DNA||Medivation/ Astellas Pharma||FDA approved August 2012|
|Chemotherapy-naïve CRPC||Inhibits CYP17 lyase, antagonizes testosterone binding to AR, degrades AR protein||Tokai Pharmaceuticals||8-arm ARMOR1 dose-escalation study completed (NCT00959959); phase II study planned|
|mCRPC, chemotherapy-naïve mCRPC||Acts as nonsteroidal, selective CYP17 lyase inhibitor||Millennium/Takeda||Separate phase III studies evaluating orteronel plus prednisone (NCT01193257, NCT01193244)|
|High-risk patients, defined by Gleason score and PSA; no distant metastases within 90 days||Radiation Therapy Oncology Group/ National Cancer Institute||Phase III study evaluating orteronel plus radiation and hormonal therapy (NCT01546987)|
|Recurrent prostate cancer after castration||Acts as pan-HDAC inhibitor||Novartis/ New York University School of Medicine||Phase I/II combination study with bicalutamide (NCT00878436)|
|Vorinostata||Given with androgen-deprivation therapy before radical prostatectomy to patients with localized prostate cancer||HDAC inhibitor||National Cancer Institute||Phase II combination study in patients with stages I-III cancer (NCT00589472)|
aVorinostat is approved under the name Zolinza for the treatment of cutaneous T-cell lymphoma.
CYP17 indicates 17 α-hydroxylase/C17,20-lyase; HDAC, histone deacetylase; mCRPC, metastatic castration-resistant prostate cancer; PSA, prostate-specific antigen.